Sanofi Highlights 31 Abstracts on Inflammatory Respiratory Diseases at ERS

Sanofi's approved and pipeline medications aimed at addressing significant care gaps in chronic inflammatory respiratory diseases will be showcased at the European Respiratory Society (ERS) International Congress.

Data from Sanofi's comprehensive immunology pipeline, including late-breaking findings from the TIDE-Asthma phase 2 study (clinical study identifier: NCT05421598) assessing amlitelimab, a fully human non-T cell depleting monoclonal antibody that inhibits OX40-ligand (OX40L), in adult patients suffering from moderate-to-severe asthma, will be highlighted.

Presentations concerning Dupixent, developed in collaboration with Regeneron, further reinforce its significance in enhancing outcomes across chronic respiratory ailments, including a late-breaking analysis from the BOREAS and NOTUS phase 3 studies focused on chronic obstructive pulmonary disease (COPD).

Moreover, results from the EVEREST phase 4 head-to-head study (clinical study identifier: NCT04998604) involving patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and concurrent asthma will be presented orally.

Also Read: Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings

“Chronic respiratory diseases can manifest through severe and aggressive symptoms and pose a significant burden on patients, which is why we are steadfast in our approach to research and treatment development,” said Alyssa Johnsen, MD, PhD, global therapeutic area head, immunology and oncology development at Sanofi. 

“Our presentations at ERS underscore our commitment to addressing unmet patient needs and our goal of helping patients breathe better. New data from our immunology pipeline reinforce our progress across novel mechanisms and modalities, including amlitelimab, for the treatment of asthma. We also look forward to sharing results from our robust clinical program for Dupixent, which offers new insights into the future of treating asthma and chronic obstructive pulmonary disease.”